BeOne Medicines (ONC) CEO John Oyler Sells $86.5M in ADSs

What Happened
John Oyler, CEO of BeOne Medicines (ONC), reported multiple open‑market sales of 240,810 ADSs between August 10 and August 12, 2026, for a total proceeds of approximately $86,480,470. Trades were executed at prices ranging roughly from $350.00 to $367.00 per ADS (the filing reports weighted average prices for several line items). The filing indicates these sales were effected pursuant to a Rule 10b5‑1 trading plan.

Key Details

• Transaction dates: Aug 10, 2026 (115,011 ADSs, ~$41.16M); Aug 11, 2026 (70,907 ADSs, ~$25.66M); Aug 12, 2026 (54,892 ADSs, ~$19.66M). Total: 240,810 ADSs, ~$86.48M.
• Price range (per ADS): reported trades ranged about $350.00–$367.00; many line items show weighted average prices and note the shares were sold in multiple transactions at specific price ranges (see footnotes in the Form 4).
• Reporting details: Form 4 filed Aug 12, 2026 (covers trades Aug 10–12); appears timely (within the usual two‑business‑day window).
• Footnotes of interest: F7 notes a Rule 10b5‑1 plan adopted Mar 10, 2026; F6 notes each ADS represents 13 ordinary shares; several footnotes indicate weighted‑average pricing and specific price ranges. Other footnotes state certain securities are held in trusts for which the reporting person disclaims beneficial ownership.
• Shares owned after transaction: not provided here — check the full Form 4 for post‑transaction holdings.

Context
These are open‑market sales by the CEO and (per the filing) were planned under a 10b5‑1 trading arrangement, which is commonly used to pre‑arrange sales and reduce concerns about trading on inside information. Sales do not by themselves indicate company prospects; purchases typically carry more direct signals about insider conviction. For exact per‑trade price breakdowns, post‑transaction holdings, and the full text of the footnotes, consult the complete Form 4 (Accession: 0001042047-26-000019).